Article Text

PDF
Higher dose l-methylfolate may be an effective adjunctive therapy for adults with major depression who have inadequate response to SSRIs

Statistics from Altmetric.com

Question

Question: In adults with major depression who have had a partial or non-response to selective serotonin reuptake inhibitors (SSRIs), is the addition of l-methylfolate effective?

Patients: 148 adults (trial 1) and 75 adults (trial 2) with Diagnostic Statistical Manual of Mental Disorders - IV (DSM-IV) major depressive disorder who had not responded to at least 8 weeks adequate treatment with an SSRI (≥20 mg/day of fluoxetine, citalopram or paroxetine; ≥10 mg/day escitalopram; or ≥50 mg/day of sertraline). Exclusion criteria: pregnancy, breastfeeding or being of child-bearing age and not using contraception; ≥25% improvement in depressive symptom severity in the 2 weeks between screening and baseline; substance use disorder within the previous 6 months; unstable medical or psychiatric illness; hypothyroidism; past failure of sufficient symptom improvement after more than two antidepressant trials; those taking supplements containing >400 µg folate or >6 µg vitamin B12.

Setting: Multicentre clinical sites in the US (both trials).

Intervention: In trial 1 participants were randomised in a 2 : 3:3 ratio to one of the three treatment groups: l-methylfolate for 60 days (7.5 mg/day for 30 days followed by 15 mg/day for 30 days); placebo for …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.